Investment Portfolio
-
Harbour BioMed
Harbour BioMed is a global clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in oncology and immunological disease areas to address unmet patient’s needs.
-
HighTide
HighTide Therapeutics is dedicated to the discovery and development of innovative therapeutics for people suffering from chronic liver diseases, gastrointestinal diseases and metabolic disorders with large and unsatisfied market needs.
-
YINUOKE
ChangChun YINUOKE Pharma Tech Co., Ltd is an innovative drug research and development company established in China in 2016. It studies disease mechanisms, develop and market products globally. YINUOKE is the first in the world to propose an innovative idea to develop cancer cachexia drugs by correcting immune disorders. Based on this idea, YINUOKE has developed several products. The key product is about to enter clinical trials in the United States.
-
Gmax Biopharm
Gmax Biopharm, founded in 2010, is an international enterprise engaged in the research, development, production and sales of GPCR antibody new drugs with "global initiative" and "best in class" potential in the field of cardiovascular, metabolic system and cancer and other major diseases in the clinical development stage.
-
Zhimeng Biopharma
Shanghai Zhimeng Biopharma Inc. is a startup biotech founded in 2017 by seasoned pharmaceutical industry veterans. Located in the economy-vibrant and resource-rich Zhangjiang High-Tech Park of Shanghai, China, Zhimeng is developing medicines for the treatment of chronic hepatitis B (CHB) and severe neurological diseases with great unmet medical needs.
-
Livingchip
Nanjing Livingchip Biotechnology Co., Ltd. was established in 2020. It uses the unique cell chip technology to engage in high-throughput single-cell antibody discovery and functional screening. It provides automated equipment and instruments, consumables and CRO services for drug R&D enterprises and scientific research institutions. It provides diagnostic reagent products and related technical services for the in vitro diagnostic (IVD) industry. The company has an internationally leading high-throughput single-cell antibody screening system with its own intellectual property rights. It is the only tech platform on the market that can achieve high-throughput screening of single-cell in situ secreted antibodies.
-
CENEROS
Genex Bio-pharmaceutical Technology (Hangzhou) Co., Ltd. was restructured and established in Hangzhou in 2018. It is a biopharmaceutical company committed to innovative drugs, with branches in the United States, Shanghai and Chengdu. The founder, Professor Fu Xinyuan, is an internationally renowned expert in molecular biology, biochemistry and medicine, as well as an entrepreneur and entrepreneur with rich experience in r&d and management.
-
Pharmacodia
Pharmacodia Information Technology (Beijing) Co., Ltd. (referred to as "Pharmacodia") was established in July 2013. Relying on big data analysis and using "data" to link "resources", the company has established a comprehensive service platform for drug research and development with structured big data. It supports different demands for data and resources at different stages in pharmaceutical research and development.
-
vbiosci
Beijing Dingchi Biotechnology Co., Ltd. is located in Beijing Economic and technological Development Zone, with an international leading research and development team, committed to improving the quality of biological drugs with international leading biopharmaceutical technology.
- Contact Us
- Click the above mail icon.
leave a message
- Contact Us
- Click the above mail icon.